Dosage of insulin treatment on newly diagnosed type 2 diabetics

Abstract

Abstract: AIM: To study the insulin dosage on newly diagnosed type 2 diabetics.Methods: Thirty-twonewly diagnosed type 2 diabetics were treated by biphasic insulin aspart 30(BIAsp30) (group Asp30, n=20) and Novolin 30R (group Novolin 30, n=12) respectively. The levels of plasma glucose and insulin dosage were evaluated.Results: There were no significant change in fasting plasma glucose and postprandial glucose before treatment in the two groups.After one week's treatment there was no significant change in fasting plasma glucose in both groups, while the postprandial plasma glucose in Asp30 was significantly lower than that in Novolin 30(P<0.05).When the controlling of plasma glucose meets the standard, the time costed in group Asp30 was significant lower compared with group Novolin 30.The maintenance dosages before breakfast and before dinner were also significantly lower in group Asp30 than that in group Novolin 30 (P<0.05) in further observation.Conclusion: It is better to use BIAsp30 than to use Novolin 30R on newly diagnosed type 2 diabetics.

Key words: type 2 diabetes, insulin analogue, plasma glucose

CLC Number:

TANG Ping, YANG Chuan, LI Li, ZENG Ying-juan, DU Jing. Dosage of insulin treatment on newly diagnosed type 2 diabetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 687-690.

References

1 Iikova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment[J].Diabetes Care, 1997, 20:1353-6
2 祝方, 纪立农, 韩学尧, 朱宇, 张红杰, 周翔海, 等.短期胰岛素强化治疗诱导初诊2 型糖尿病患者血糖长期良好控制的临床实验[J].糖尿病杂志, 2003;11:5-9
3 Lebovitz H.Postprandial hypergly caemec state:importance and consequences[J].Diabetes Res Clin Pract, 1998;40:S27-8
4 Balkau B, Shipley M, Jarrett R.High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men.20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman Study[J].Diabetes Care, 1998;21:360-7
5 Tominaga M, Eguchi H, Manaka H, Igarishi K, Kato T, Sekikawa A.Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose[J].Diabetes Care, 1999;22:920-4
6 Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kolendorf K, Madsbad S.Improved postprandial glycemic contros with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes[J].Diabetes Care, 2002;25:883-8
7 Mcsorley P, Bell P, Jacobsen L, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30:a double-blind cross-over study in people with Type 2 diabetes[J].Clin Ther, 2002;24:530-9
8 Overmann H, Heinemann L.Injection-meal interval:recommendations of diabetologists and how patients handle it[J].Diabetes Res Clin Pract, 1999;43:137-42
9 Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L.Use of inslulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes[J].Diabetes Care, 2000;23:583-8
10 Boehm B, Home P, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily:a randomized trial in Type 1 and Type 2 diabetic patients[J].Diabet Med, 2002;19:393-9
11 Weyer C, Heise T, Heinemann L.Insulin aspart in a 30/70 premixed formulation.Pharmacodynamic properties of a rapidacting insulin analog in stable mixture[J].Diabetes Care, 1997; 20:1612-4

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[4]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[5]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[6]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[7]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[8]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[9]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[10]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[11]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[12]	CHEN Qian, WANG Yafeng, DUO Delong, CHANG Ya'e, YAN Yingjun, DUAN Kunkun. Trigliptin succinate have an effect on gut microbiota of type 2 diabetic mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 15-24.
[13]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[14]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[15]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.